190 related articles for article (PubMed ID: 34437635)
21. [Current management of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Onizuka M
Rinsho Ketsueki; 2018; 59(10):2028-2035. PubMed ID: 30305505
[TBL] [Abstract][Full Text] [Related]
22. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
Issa GC; Kantarjian HM; Yin CC; Qiao W; Ravandi F; Thomas D; Short NJ; Sasaki K; Garcia-Manero G; Kadia TM; Cortes JE; Daver N; Borthakur G; Jain N; Konopleva M; Khouri I; Kebriaei P; Champlin RE; Pierce S; O'Brien SM; Jabbour E
Cancer; 2017 Feb; 123(3):459-467. PubMed ID: 27696391
[TBL] [Abstract][Full Text] [Related]
24. Is stem cell transplantation still needed for adult Philadelphia chromosome-positive acute lymphoblastic leukemia receiving tyrosine kinase inhibitors therapy?: A systematic review and meta-analysis.
Ponvilawan B; Kungwankiattichai S; Charoenngam N; Owattanapanich W
PLoS One; 2021; 16(6):e0253896. PubMed ID: 34181696
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
[TBL] [Abstract][Full Text] [Related]
26. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.
Nagafuji K; Miyamoto T; Eto T; Ogawa R; Okumura H; Takase K; Kawano N; Miyazaki Y; Fujisaki T; Wake A; Ohno Y; Kurokawa T; Kamimura T; Takamatsu Y; Yokota S; Akashi K
Eur J Haematol; 2019 Sep; 103(3):164-171. PubMed ID: 31132205
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of CD20 Expression in Children with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
Wang Y; Xue YJ; Jia YP; Zuo YX; Lu AD; Zhang LP
Acta Haematol; 2023; 146(5):349-357. PubMed ID: 37212472
[TBL] [Abstract][Full Text] [Related]
28. [Intensive chemotherapy with tyrosine kinase inhibitors in philadelphia-positive acute lymphoblastic leukemia].
Benavente R; Cid F; Puga B; Molina J; Bass F; Andrade A; Monardes V; Encina A; Cabrera ME
Rev Med Chil; 2021 Sep; 149(9):1249-1257. PubMed ID: 35319677
[TBL] [Abstract][Full Text] [Related]
29. PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.
Ferrari LC; Rivas MM; Navickas AB; Dick H; Mela Osorio MJ; Agamennoni L; Rey IH; Carnelutto NE; Cazap N; Castro MB; Aranguren PN; Fischman LA; Yupanki ML; Milone JH; Fernández II; Moirano MM; Belli CB;
Ann Hematol; 2023 May; 102(5):1087-1097. PubMed ID: 36892593
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
31. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.
Cassaday RD; Stevenson PA; Wood BL; Becker PS; Hendrie PC; Sandmaier BM; Radich JL; Shustov AR
Am J Hematol; 2018 Aug; 93(4):546-552. PubMed ID: 29318644
[TBL] [Abstract][Full Text] [Related]
32. The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zhang Y; Feng S
Leuk Res; 2021 Oct; 109():106647. PubMed ID: 34325192
[TBL] [Abstract][Full Text] [Related]
33. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
[TBL] [Abstract][Full Text] [Related]
34. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic analysis of children with Philadelphia chromosome-like acute lymphoblastic leukemia common genes].
Hu WD; Li B; Su SF; Liu YF; Liu W; Zhang WL; Zuo WL; Yu RH
Zhonghua Er Ke Za Zhi; 2023 May; 61(5):446-452. PubMed ID: 37096265
[No Abstract] [Full Text] [Related]
36. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.
Yoon JH; Min GJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
Cancer; 2019 Mar; 125(6):873-883. PubMed ID: 30521062
[TBL] [Abstract][Full Text] [Related]
37. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
[TBL] [Abstract][Full Text] [Related]
38. A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.
Ribera JM; Morgades M; Montesinos P; Tormo M; Martínez-Carballeira D; González-Campos J; Gil C; Barba P; García-Boyero R; Coll R; Pedreño M; Ribera J; Mercadal S; Vives S; Novo A; Genescà E; Hernández-Rivas JM; Bergua J; Amigo ML; Vall-Llovera F; Martínez-Sánchez P; Calbacho M; García-Cadenas I; Garcia-Guiñon A; Sánchez-Sánchez MJ; Cervera M; Feliu E; Orfao A;
Cancer Med; 2020 Apr; 9(7):2317-2329. PubMed ID: 32022463
[TBL] [Abstract][Full Text] [Related]
39. Comparative study on allogeneic with autologous hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of TKIs: a systematic review and meta-analysis.
Wei H; Kuang P; Liu T
Ann Hematol; 2020 Nov; 99(11):2619-2628. PubMed ID: 32960314
[TBL] [Abstract][Full Text] [Related]
40. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
